MARKET

ORKA

ORKA

Oruka Therapeutics Inc
NASDAQ
28.15
-0.23
-0.81%
After Hours: 28.51 +0.36 +1.28% 16:22 12/18 EST
OPEN
29.26
PREV CLOSE
28.38
HIGH
30.09
LOW
27.84
VOLUME
626.98K
TURNOVER
--
52 WEEK HIGH
32.28
52 WEEK LOW
5.49
MARKET CAP
1.36B
P/E (TTM)
-11.9153
1D
5D
1M
3M
1Y
5Y
1D
ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors
TipRanks · 15h ago
Oruka Therapeutics initiated with an Overweight at Piper Sandler
TipRanks · 20h ago
ORUKA THERAPEUTICS INC <ORKA.O>: PIPER SANDLER INITIATES COVERAGE WITH OVERWEIGHT RATING; PRICE TARGET $75
Reuters · 22h ago
U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar
Reuters · 1d ago
Weekly Report: what happened at ORKA last week (1208-1212)?
Weekly Report · 3d ago
Oruka Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Christopher Nathan Martin
Reuters · 12/11 21:33
Oruka Therapeutics Appoints Christopher Martin to Board
TipRanks · 12/11 21:31
Oruka Therapeutics Appoints Chris Martin to Board as Cameron Turtle Resigns
Reuters · 12/11 21:01
More
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Webull offers Oruka Therapeutics Inc stock information, including NASDAQ: ORKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORKA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORKA stock methods without spending real money on the virtual paper trading platform.